Insomnia symptoms predict longer COVID-19 symptom duration.
Insomnia symptoms predict longer COVID-19 symptom duration.
复制标题
DOI：
10.1016/j.sleep.2022.11.019
复制
发表时间：
2023-01
期刊：
影响因子：
4.8
通讯作者：
Perlis, Michael L.
中科院分区：
文献类型：
--
作者：
Vargas, Ivan;Muench, Alexandria;Grandner, Michael A.;Irwin, Michael R.;Perlis, Michael L.
/背景：本研究的目的是评估COVID-19大流行期间美国失眠的患病率和发生率，以及在感染COVID-19的人群中，失眠是否预示着更糟糕的结果（例如，更频繁、持续时间更长或更严重的症状）。在COVID-19大流行期间的两个时间点（T1 = 2020年4月至6月; T2 = 2021年1月至3月），对2980名居住在美国的成年人进行了在线调查。在这两个时间点使用Insulin严重程度指数（ISI）评估Insulin症状。T2调查还询问了有关COVID-19检测和症状的问题。失眠（定义为ISI ≥15）的患病率在T1时为15%，在T2时为13%。失眠的发生率（即，T1 ~ T2新发病例占5.6%。相对于没有失眠的参与者，失眠的参与者感染COVID-19的可能性并不高。在我们样本中在研究期间感染病毒的参与者（n = 149）中，COVID-19症状结果没有显著的组间差异，但有一个例外，失眠的参与者更有可能报告更长的症状持续时间（失眠= 24.8个病假，无失眠= 16.1个病假）。目前的研究表明，在COVID-19大流行期间，美国人口的失眠患病率仍然很高。数据还支持失眠可能与经历更多慢性COVID-19症状有关。这些发现对睡眠和失眠对免疫功能的作用具有更普遍的意义。
/Background: The goal of the present study was to assess the prevalence and incidence of insomnia in the United States during the COVID-19 pandemic, and whether, among those that contracted COVID-19, insomnia predicted worse outcomes (e.g., symptoms of greater frequency, duration, or severity). A nationwide sample of 2980 adults living in the United States were surveyed online at two points during the COVID-19 pandemic (T1 = April–June 2020; T2 = January–March 2021). Insomnia symptoms were assessed at both time points using the Insomnia Severity Index (ISI). The T2 survey also asked questions regarding COVID-19 testing and symptoms. The prevalence of insomnia (defined as ISI ≥15) was 15% at T1 and 13% at T2. The incidence rate of insomnia (i.e., new cases from T1 to T2) was 5.6%. Participants with insomnia were not more likely to contract COVID-19 relative to those participants without insomnia. Among those participants in our sample that contracted the virus during the study interval (n = 149), there were no significant group differences in COVID-19 symptom outcomes, with one exception, participants with insomnia were more likely to report a longer symptom duration (insomnia = 24.8 sick days, no insomnia = 16.1 sick days). The present study suggests the prevalence of insomnia in the U.S. population remained high during the COVID-19 pandemic. The data also support that insomnia may be related to experiencing more chronic COVID-19 symptoms. These findings have more general implications for the role of sleep and insomnia on immune functioning.
登录
查看更多内容
影响因子：
4.8
作者：
Bhat S;Chokroverty S
通讯作者：
Chokroverty S
影响因子：
3.4
作者：
Brandão LEM;Martikainen T;Merikanto I;Holzinger B;Morin CM;Espie CA;Bolstad CJ;Leger D;Chung F;Plazzi G;Dauvilliers Y;Matsui K;De Gennaro L;Sieminski M;Nadorff MR;Chan NY;Wing YK;Mota-Rolim SA;Inoue Y;Partinen M;Benedict C;Bjorvatn B;Cedernaes J
通讯作者：
Cedernaes J
影响因子：
--
作者：
Abdulah, Deldar Morad;Musa, Dildar Haji
通讯作者：
Musa, Dildar Haji
影响因子：
4.8
作者：
Bastien, Celyne H.;Vallieres, Annie;Morin, Charles M.
通讯作者：
Morin, Charles M.
影响因子：
5.6
作者：
Mills, Paul J.;von Kaenel, Roland;Dimsdale, Joel E.
通讯作者：
Dimsdale, Joel E.